How to Help Your Patients Find Flecainide in Stock: A Provider's Guide

If you prescribe flecainide, you've likely fielded calls from patients who can't fill their prescription. Pharmacy inventory gaps — even without a formal FDA shortage — are a real and recurring problem for this cardiac medication. This guide gives you actionable tools and prescribing strategies to help your patients stay on therapy without dangerous gaps.

Why Flecainide Availability Is a Clinical Priority

Flecainide is not a medication where supply gaps are medically trivial. Patients prescribed flecainide have serious arrhythmias — paroxysmal atrial fibrillation, PSVT, or life-threatening ventricular tachycardia. Discontinuing therapy without a plan invites arrhythmia recurrence, emergency department visits, and potential cardiovascular events.

With flecainide's half-life of 12–27 hours, a patient who runs out today may experience arrhythmia recurrence within 24–72 hours. That urgency means providers need an efficient response workflow — not just clinical guidance, but practical logistics.

Step 1: Set Expectations at the Time of Prescribing

The best time to prevent a supply crisis is before it happens. When you initiate flecainide, counsel your patients on the following:

• "This medication may not always be available at every pharmacy. Begin looking for your refill at least one week before you run out."
• "Never stop taking flecainide abruptly. Call us if you're having trouble filling it."
• "If your pharmacy is out of stock, you can transfer your prescription to another pharmacy without needing a new prescription."

Step 2: Prescribe a 90-Day Supply When Possible

For stable patients on chronic flecainide therapy, a 90-day supply significantly reduces the frequency of refill-related supply gaps. Mail-order pharmacies — available through most insurance plans — are often the most reliable source for 90-day supplies and typically have consistent stock for long-term cardiac medications.

A 90-day supply also typically costs less per tablet than a 30-day supply under most commercial plans and Medicare Part D. This is a clinical and financial win for patients.

Step 3: Allow Generic Substitution (and Document It)

Brand-name Tambocor is rarely stocked at retail pharmacies. If your prescription specifies brand-only for any reason, consider switching to generic-acceptable to dramatically improve your patient's ability to fill the prescription. Multiple generic manufacturers produce bioequivalent flecainide acetate, and switching generic suppliers has not been shown to affect therapeutic outcomes in this drug class.

Step 4: Recommend medfinder for Pharmacy Searches

Instead of having your staff spend 20–30 minutes calling pharmacies for a patient, direct them to medfinder for Providers. medfinder calls pharmacies near the patient's location to find which ones have their specific flecainide strength in stock and texts the results to the patient. This reduces the burden on your clinical staff while giving patients actionable information fast.

Step 5: Know Which Local Pharmacies Reliably Stock Flecainide

Over time, your office may identify one or two pharmacies in your area that consistently stock flecainide — often hospital-affiliated pharmacies or certain independent pharmacies with a cardiology customer base. Maintaining a short list of reliable pharmacies to recommend when patients report stock issues reduces time-to-resolution significantly.

When a Patient Calls With an Urgent Stock Gap

When a patient is within 1–2 days of running out and has not been able to locate flecainide, your clinical response should be:

1. Triage for arrhythmia risk. Assess whether the patient's underlying arrhythmia is symptomatic or has been stable. Patients with recent AFib breakthrough or recurrent symptomatic PSVT need faster resolution.
2. Attempt a broader pharmacy search. Direct your staff or the patient to medfinder, or ask your MA to call 3–4 local pharmacies including hospital pharmacies.
3. Consider a partial fill authorization. If a nearby pharmacy has a partial supply, authorize a partial fill to bridge until the full quantity is available elsewhere.
4. Evaluate short-term alternative only if unavoidable. If stock truly cannot be located within 24 hours for a high-risk patient, discuss whether a short-term bridge with propafenone or another Class IC agent is clinically appropriate. Document rationale thoroughly.

Building a Flecainide Availability Protocol at Your Practice

Practices with a significant cardiology or EP population benefit from a simple written workflow for flecainide supply gaps. A one-page protocol covering triage criteria, trusted local pharmacies, partial fill authorization, and escalation criteria reduces staff decision fatigue and speeds resolution when the next call comes in.

For a broader clinical overview of the current availability situation, see our flecainide shortage guide for providers.